NASDAQ:NKTR - Nektar Therapeutics Stock Price, Price Target & More

$84.74 -0.71 (-0.83 %)

(As of 04/24/2018 10:42 AM ET)

Previous Close$85.45

Today's Range$83.30 - $87.00

52-Week Range$17.33 - $111.36

Volume415,270 shs

Average Volume3.02 million shs

Market Capitalization$13.87 billion

P/E Ratio-155.36

Dividend YieldN/A

Beta1.73

About Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain based on its PEGylation and polymer conjugate technology platforms in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology. It is also developing MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; ADYNOVATE for hemophilia A; Somavert to treat acromegaly; and Neulasta for treating neutropenia. In addition, the company develops PEG-INTRON for the treatment of hepatitis-C; Macugen for age-related macular degeneration; CIMZIA to treat rheumatoid arthritis, Crohn's disease, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia related to chronic kidney disease in patients on and not on dialysis. Further, it is developing SEMPRANA to treat migraine; dapirolizumab pegol for systemic lupus erythematosus; PEGPH20 for ancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreements with AstraZeneca AB, Shire plc, Pfizer Inc., Amgen Inc., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Allergan, Inc., Halozyme Therapeutics, Inc., Baxalta Incorporated, and Bristol-Myers Squibb Company. The company was founded in 1990 and is headquartered in San Francisco, California.

Receive NKTR News and Ratings via Email

Sign-up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

SymbolNASDAQ:NKTR

CUSIP64026810

Webwww.nektar.com

Phone415-482-5300

Debt

Debt-to-Equity Ratio2.79%

Current Ratio5.82%

Quick Ratio5.63%

Price-To-Earnings

Trailing P/E Ratio-155.36

Forward P/E Ratio-59.26

P/E GrowthN/A

Sales & Book Value

Annual Sales$30.71 million

Price / Sales444.04

Cash FlowN/A

Price / CashN/A

Book Value$0.56 per share

Price / Book151.32

Profitability

EPS (Most Recent Fiscal Year)($0.55)

Net Income$-96,690,000.00

Net Margins-31.42%

Return on Equity-156.85%

Return on Assets-16.48%

Miscellaneous

Employees509

Outstanding Shares160,920,000

How to Become a New Pot Stock Millionaire

Nektar Therapeutics (NASDAQ:NKTR) Frequently Asked Questions

What is Nektar Therapeutics' stock symbol?

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

How were Nektar Therapeutics' earnings last quarter?

Nektar Therapeutics (NASDAQ:NKTR) announced its quarterly earnings data on Thursday, March, 1st. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.35) by $0.14. The biopharmaceutical company had revenue of $95.47 million for the quarter, compared to analysts' expectations of $36.96 million. Nektar Therapeutics had a negative return on equity of 156.85% and a negative net margin of 31.42%. Nektar Therapeutics's revenue for the quarter was up 154.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.28) earnings per share. View Nektar Therapeutics' Earnings History.

When is Nektar Therapeutics' next earnings date?

Nektar Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Nektar Therapeutics.

What price target have analysts set for NKTR?

13 brokers have issued 1-year price targets for Nektar Therapeutics' stock. Their forecasts range from $20.00 to $125.00. On average, they anticipate Nektar Therapeutics' share price to reach $79.75 in the next year. View Analyst Ratings for Nektar Therapeutics.

What are Wall Street analysts saying about Nektar Therapeutics stock?

Here are some recent quotes from research analysts about Nektar Therapeutics stock:

1. Mizuho analysts commented, "We believe Keytruda’s data reinforces our thesis on Nektar. Assuming positive data at ASCO, we believe BMS would be inclined to make a bid for Nektar given its deteriorating market position relative to Merck." (4/17/2018)
2. According to Zacks Investment Research, "Nektar has a promising pipeline, with several updates lined up for the next several quarters. Additionally, regular partnerships have enhanced the company’s financial position. Nektar stands to receive significant sales milestone payment plus royalties for Movantik under the license agreement with AstraZeneca. Also, its recent codevelopment deal with Lilly for NKTR-358 is encouraging. On the flip side, Nektar relies heavily on partners for revenues. Partnership-related setbacks may thus weigh heavily on the company, while disappointing products sales could leave an adverse impact on its financial results. Moreover, competition from various pharmaceutical and biotechnology companies is another matter of concern. Shares of the company have significantly outperformed the industry in the last one year." (2/21/2018)

Who are some of Nektar Therapeutics' key competitors?

Some companies that are related to Nektar Therapeutics include Allergan (AGN), Shire (SHPG), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Takeda Pharmaceutical (TKPYY), Regeneron (REGN), Astellas Pharma (ALPMY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Mylan (MYL), Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Grifols (GRFS) and Ono Pharmaceutical (OPHLF).

Who are Nektar Therapeutics' key executives?

Nektar Therapeutics' management team includes the folowing people:

Mr. Howard W. Robin, CEO, Pres & Director (Age 65)
Mr. Gil M. Labrucherie, Sr. VP & CFO (Age 46)
Mr. John Nicholson, Sr. VP & COO (Age 66)
Dr. Maninder Hora, Sr. VP of Pharmaceutical Devel. and Chief Technical Operations Officer (Age 64)
Ms. Jillian B. Thomsen, Sr. VP of Fin. & Chief Accounting Officer (Age 52)

Has Nektar Therapeutics been receiving favorable news coverage?

News coverage about NKTR stock has been trending somewhat positive this week, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Nektar Therapeutics earned a news impact score of 0.20 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 47.26 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Who are Nektar Therapeutics' major shareholders?

Nektar Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (12.28%) and FMR LLC (12.28%). Company insiders that own Nektar Therapeutics stock include Christopher A Kuebler, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jillian B Thomsen, John Nicholson, Lutz Lingnau, Maninder Hora, R Scott Greer, Robert Chess, Roy A Whitfield and Stephen K Doberstein. View Institutional Ownership Trends for Nektar Therapeutics.

How do I buy shares of Nektar Therapeutics?

Shares of NKTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nektar Therapeutics' stock price today?

One share of NKTR stock can currently be purchased for approximately $84.74.

How big of a company is Nektar Therapeutics?

Nektar Therapeutics has a market capitalization of $13.87 billion and generates $30.71 million in revenue each year. The biopharmaceutical company earns $-96,690,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. Nektar Therapeutics employs 509 workers across the globe.

How can I contact Nektar Therapeutics?

Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-482-5300 or via email at [email protected]

MarketBeat Community Rating for Nektar Therapeutics (NKTR)

Community Ranking:		3.5 out of 5 ( )
Outperform Votes:		403 (Vote Outperform)
Underperform Votes:		181 (Vote Underperform)
Total Votes:		584

MarketBeat's community ratings are surveys of what our community members think about Nektar Therapeutics and other stocks. Vote "Outperform" if you believe NKTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NKTR will underperform the S&P 500 over the long term. You may vote once every thirty days.

Nektar Therapeutics (NASDAQ:NKTR) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

13 Wall Street analysts have issued ratings and price targets for Nektar Therapeutics in the last 12 months. Their average twelve-month price target is $79.75, suggesting that the stock has a possible downside of 5.89%. The high price target for NKTR is $125.00 and the low price target for NKTR is $20.00. There are currently 1 hold rating and 12 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.92	2.92	2.92	2.90
Ratings Breakdown:	0 Sell Rating(s) 1 Hold Rating(s) 12 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 11 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 12 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 9 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$79.75	$57.5455	$48.1818	$27.1111
Price Target Upside:	5.89% downside	44.06% downside	32.70% downside	18.23% upside

Nektar Therapeutics (NASDAQ:NKTR) Consensus Price Target History

Price Target History for Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics (NASDAQ:NKTR) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/20/2018	Seaport Global Securities	Initiated Coverage	Buy	$120.00	Low
4/17/2018	HC Wainwright	Set Price Target	Buy	$125.00	Low
4/17/2018	Mizuho	Reiterated Rating	Buy	$103.00	Low
4/13/2018	Piper Jaffray	Initiated Coverage	Overweight -> Overweight	$125.00	Medium
3/2/2018	Cowen	Reiterated Rating	Buy	$101.00	Low
3/2/2018	Jefferies Group	Boost Price Target	Buy	$103.00	High
3/2/2018	Canaccord Genuity	Boost Price Target	Buy -> Buy	$94.00	High
11/13/2017	Roth Capital	Set Price Target	Buy	$45.00	N/A
11/13/2017	JPMorgan Chase	Reiterated Rating	Positive -> Buy	$44.00	N/A
8/17/2017	Evercore ISI	Initiated Coverage	In -> In-Line	$20.00	High
7/18/2017	William Blair	Reiterated Rating	Outperform		Low
5/10/2017	Aegis	Reiterated Rating	Buy	$27.00	High
3/21/2017	BTIG Research	Boost Price Target	Positive	$22.00 -> $27.00	Medium
9/30/2016	Brean Capital	Reiterated Rating	Buy	$23.00	N/A

(Data available from 4/24/2016 forward)

Nektar Therapeutics (NASDAQ:NKTR) Earnings History and Estimates Chart

Earnings by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics (NASDAQ:NKTR) Earnings Estimates

2018 EPS Consensus Estimate: ($1.01)
2019 EPS Consensus Estimate: ($3.63)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	($0.32)	($0.12)	($0.22)
Q2 2018	2	($0.32)	($0.13)	($0.23)
Q3 2018	2	($0.33)	($0.13)	($0.23)
Q4 2018	1	($0.33)	($0.33)	($0.33)
Q1 2019	1	($0.87)	($0.87)	($0.87)
Q2 2019	1	($0.89)	($0.89)	($0.89)
Q3 2019	1	($0.92)	($0.92)	($0.92)
Q4 2019	1	($0.95)	($0.95)	($0.95)

Nektar Therapeutics (NASDAQ NKTR) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/7/2018		($0.27)					N/A
3/1/2018	Q4 2017	($0.35)	($0.21)	$36.96 million	$95.47 million	View	Listen
11/7/2017	Q3 2017	$0.21	$0.3740	$126.50 million	$152.90 million	View	N/A
8/8/2017	Q2 2017	($0.35)	($0.39)	$33.64 million	$34.60 million	View	Listen
5/9/2017	Q1 2017	($0.40)	($0.42)	$29.43 million	$24.73 million	View	Listen
3/1/2017	Q416	($0.26)	($0.28)	$40.83 million	$37.45 million	View	Listen
11/3/2016	Q316	($0.36)	($0.32)	$32.42 million	$36.30 million	View	N/A
8/3/2016	Q216	($0.33)	($0.36)	$34.17 million	$32.77 million	View	Listen
5/3/2016	Q1	($0.23)	($0.14)	$43.78 million	$58.88 million	View	N/A
3/1/2016	Q4	($0.42)	($0.40)	$28.82 million	$39.40 million	View	Listen
11/5/2015	Q315	($0.30)	($0.06)	$44.30 million	$60.00 million	View	N/A
8/5/2015	Q215	($0.40)	($0.40)	$21.49 million	$22.66 million	View	N/A
4/30/2015	Q115	($0.40)	$0.25	$20.20 million	$108.80 million	View	N/A
2/24/2015	Q414	($0.36)	($0.35)	$12.30 million	$19.55 million	View	N/A
11/6/2014	Q314	$0.39	$0.53	$123.20 million	$132.90 million	View	N/A
7/31/2014	Q214	($0.38)	($0.26)	$19.76 million	$28.50 million	View	Listen
5/7/2014	Q114	($0.35)	($0.37)	$38.68 million	$19.80 million	View	Listen
2/26/2014	Q413	($0.17)	($0.41)	$49.26 million	$31.15 million	View	N/A
11/7/2013	Q313	($0.22)	($0.14)	$54.34 million	$60.91 million	View	N/A
8/8/2013	Q2 2013	($0.44)	($0.37)	$26.22 million	$33.86 million	View	N/A
5/9/2013	Q1 2013	($0.42)	($0.48)	$26.30 million	$23.00 million	View	N/A
2/28/2013	Q4 2012	($0.45)	($0.46)			View	N/A
11/9/2012	Q312	($0.39)	($0.38)	$21.02 million	$18.41 million	View	N/A
8/9/2012		($0.33)	($0.30)			View	N/A
5/2/2012		($0.33)	($0.36)			View	N/A
2/29/2012		($0.47)	($0.33)			View	N/A
11/2/2011		($0.37)	($0.21)			View	N/A
8/4/2011		($0.31)	($0.32)			View	N/A
4/27/2011		($0.27)	($0.33)			View	N/A
3/1/2011	Q4 2010	($0.16)	($0.11)			View	N/A
11/4/2010	Q3 2010	($0.05)	($0.09)			View	N/A
7/28/2010	Q2 2010	($0.09)	($0.01)			View	N/A
5/5/2010	Q1 2010	($0.09)	($0.07)			View	N/A
3/2/2010	Q4 2009	$0.08	($0.08)			View	N/A
11/4/2009	Q3 2009	($0.40)	($0.33)			View	N/A
8/4/2009	Q2 2009	($0.42)	($0.35)			View	N/A
5/6/2009	Q1 2009	($0.41)	($0.34)			View	N/A
2/24/2009	Q4 2008	($0.31)	($0.46)			View	N/A
11/6/2008	Q3 2008	($0.29)	($0.40)			View	N/A
8/6/2008	Q2 2008	($0.31)	($0.36)			View	N/A
5/7/2008	Q1 2008	($0.27)	($0.44)			View	N/A
2/27/2008	Q4 2007	($0.25)	($0.13)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Nektar Therapeutics (NASDAQ:NKTR) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Nektar Therapeutics (NASDAQ NKTR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.44%
Institutional Ownership Percentage: 96.31%

Insider Trading History for Nektar Therapeutics (NASDAQ:NKTR)

Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics (NASDAQ NKTR) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/16/2018	Jillian B. Thomsen	SVP	Sell	13,881	$101.46	$1,408,366.26
4/9/2018	Stephen K Doberstein	SVP	Sell	160,000	$93.06	$14,889,600.00	127,394
4/6/2018	Robert Chess	Director	Sell	25,000	$92.14	$2,303,500.00	284,223
4/5/2018	Maninder Hora	SVP	Sell	20,000	$101.75	$2,035,000.00	127,394
3/7/2018	Christopher A Kuebler	Director	Sell	40,000	$97.60	$3,904,000.00	43,100
3/7/2018	John Nicholson	COO	Sell	220,144	$99.27	$21,853,694.88	267,657
2/16/2018	Gil M. Labrucherie	CFO	Sell	3,477	$82.94	$288,382.38
2/16/2018	Howard W Robin	CEO	Sell	12,788	$82.94	$1,060,636.72	237,147
2/16/2018	Jillian B. Thomsen	CAO	Sell	2,545	$82.94	$211,082.30
2/16/2018	John Nicholson	COO	Sell	4,879	$82.94	$404,664.26	387,657
2/16/2018	Stephen K Doberstein	SVP	Sell	2,426	$82.94	$201,212.44	67,394
1/22/2018	Howard W Robin	CEO	Sell	83,333	$75.82	$6,318,308.06	333,268
1/2/2018	Christopher A Kuebler	Director	Sell	30,000	$58.66	$1,759,800.00	70,500
12/13/2017	Howard W Robin	CEO	Sell	83,333	$55.69	$4,640,814.77	272,768
11/13/2017	John Nicholson	COO	Sell	15,910	$37.78	$601,079.80	249,066
11/8/2017	Stephen K Doberstein	SVP	Sell	396,323	$29.00	$11,493,367.00	52,016
11/6/2017	Maninder Hora	SVP	Sell	5,117	$25.07	$128,283.19	52,016
11/1/2017	Howard W Robin	CEO	Sell	83,334	$23.57	$1,964,182.38	235,838
10/9/2017	Howard W Robin	CEO	Sell	83,333	$24.20	$2,016,658.60
10/5/2017	Stephen K Doberstein	SVP	Sell	43,677	$24.97	$1,090,614.69
10/2/2017	Gil M. Labrucherie	CFO	Sell	120,000	$24.45	$2,934,000.00
10/2/2017	Ivan P Gergel	SVP	Sell	100,000	$24.14	$2,414,000.00	84,871
9/22/2017	Christopher A Kuebler	Director	Sell	4,000	$21.86	$87,440.00	40,500
9/21/2017	Robert Chess	Director	Sell	6,400	$21.72	$139,008.00	274,223
9/6/2017	Howard W Robin	CEO	Sell	83,333	$21.54	$1,794,992.82	235,837
8/16/2017	Howard W Robin	CEO	Sell	91,714	$19.26	$1,766,411.64	152,504
8/16/2017	Jillian B. Thomsen	CAO	Sell	2,648	$19.32	$51,159.36
8/16/2017	John Nicholson	COO	Sell	3,177	$19.32	$61,379.64	224,066
8/16/2017	Stephen K Doberstein	SVP	Sell	1,701	$19.32	$32,863.32	31,102
8/10/2017	Roy A Whitfield	Director	Buy	35,000	$17.95	$628,250.00	133,000
7/18/2017	Ivan P Gergel	SVP	Sell	54,920	$21.10	$1,158,812.00	98,492
7/14/2017	Lutz Lingnau	Director	Sell	30,000	$20.76	$622,800.00	53,450
7/12/2017	Ivan P Gergel	SVP	Sell	45,080	$21.08	$950,286.40	51,961
7/11/2017	Ivan P Gergel	SVP	Sell	8,389	$21.04	$176,504.56	51,961
5/16/2017	Gil M. Labrucherie	CFO	Sell	3,179	$19.55	$62,149.45
5/16/2017	Howard W Robin	CEO	Sell	8,388	$19.55	$163,985.40	160,884
5/16/2017	John Nicholson	COO	Sell	3,146	$19.55	$61,504.30	178,943
5/16/2017	Stephen K Doberstein	SVP	Sell	1,701	$19.55	$33,254.55	32,803
5/15/2017	Robert Chess	Director	Sell	5,000	$19.79	$98,950.00	276,623
4/17/2017	Robert Chess	Director	Sell	5,000	$18.72	$93,600.00	276,623
4/7/2017	Lutz Lingnau	Director	Sell	7,000	$20.05	$140,350.00	23,450
4/5/2017	Christopher A Kuebler	Director	Sell	15,000	$21.88	$328,200.00	50,500
4/5/2017	Maninder Hora	SVP	Sell	180,000	$21.70	$3,906,000.00
3/20/2017	Jillian B. Thomsen	SVP	Sell	112,500	$19.69	$2,215,125.00
3/3/2017	Gil M. Labrucherie	CFO	Sell	200,000	$15.16	$3,032,000.00
2/16/2017	Gil M. Labrucherie	CFO	Sell	2,359	$13.14	$30,997.26
2/16/2017	Howard W Robin	CEO	Sell	8,636	$13.14	$113,477.04	169,272
2/16/2017	Ivan P Gergel	SVP	Sell	1,457	$13.14	$19,144.98	45,022
2/16/2017	John Nicholson	COO	Sell	3,237	$13.14	$42,534.18	182,089
2/8/2017	Howard W Robin	CEO	Sell	87,500	$13.04	$1,141,000.00	265,408
2/3/2017	John Nicholson	COO	Sell	75,000	$12.39	$929,250.00	206,821
1/17/2017	Howard W Robin	CEO	Sell	87,500	$12.35	$1,080,625.00	265,408
11/17/2016	Howard W Robin	CEO	Sell	93,458	$13.88	$1,297,197.04	122,908
10/24/2016	R Scott Greer	Director	Buy	15,000	$13.50	$202,500.00	121,333
10/4/2016	Howard W. Robin	CEO	Sell	87,500	$17.06	$1,492,750.00
9/16/2016	Christopher A. Kuebler	Director	Sell	7,500	$19.13	$143,475.00
9/15/2016	Robert Chess	Director	Sell	12,000	$19.21	$230,520.00
9/1/2016	Howard W. Robin	CEO	Sell	87,500	$17.83	$1,560,125.00
8/16/2016	Gil M. Labrucherie	CFO	Sell	3,305	$17.56	$58,035.80
8/16/2016	Howard W. Robin	CEO	Sell	11,817	$17.56	$207,506.52
8/16/2016	John Nicholson	COO	Sell	3,317	$17.56	$58,246.52
8/16/2016	Stephen K. Doberstein	SVP	Sell	1,336	$17.56	$23,460.16
8/1/2016	Robert Chess	Director	Sell	5,000	$17.26	$86,300.00
7/11/2016	Jillian B Thomsen	CAO	Sell	100,000	$15.09	$1,509,000.00	106,809
7/1/2016	Robert Chess	Director	Sell	5,000	$14.10	$70,500.00
5/17/2016	Gil M Labrucherie	SVP	Sell	836	$13.58	$11,352.88	8,757
5/17/2016	Howard W Robin	CEO	Sell	2,170	$13.58	$29,468.60	19,103
5/17/2016	Jillian B Thomsen	CAO	Sell	724	$13.58	$9,831.92	7,033
5/17/2016	John Nicholson	CFO	Sell	856	$13.58	$11,624.48	78,486
4/25/2016	Lutz Lingnau	Director	Sell	15,000	$16.27	$244,050.00	31,450
2/17/2016	Howard W. Robin	CEO	Sell	2,147	$11.92	$25,592.24	13,478
2/17/2016	Jillian B. Thomsen	CAO	Sell	716	$11.92	$8,534.72	5,158
2/17/2016	Maninder Hora	SVP	Sell	963	$11.92	$11,478.96	5,803
2/10/2016	Gil M. Labrucherie	SVP	Sell	11,666	$11.49	$134,042.34	5,251
2/10/2016	Howard W. Robin	CEO	Sell	66,666	$11.49	$765,992.34	10,000
2/10/2016	Jillian B. Thomsen	CAO	Sell	15,000	$11.49	$172,350.00	3,999
1/20/2016	Lutz Lingnau	Director	Sell	15,000	$14.51	$217,650.00	16,450
1/19/2016	Gil M. Labrucherie	SVP	Sell	11,667	$14.12	$164,738.04	5,251
1/19/2016	Howard W. Robin	CEO	Sell	66,667	$14.12	$941,338.04	10,000
1/19/2016	Jillian B. Thomsen	CAO	Sell	15,000	$14.12	$211,800.00	3,999
12/4/2015	Christopher A. Kuebler	Director	Sell	15,000	$15.82	$237,300.00	20,000
12/3/2015	Gil M. Labrucherie	SVP	Sell	45,001	$15.87	$714,165.87	5,251
12/3/2015	Howard W. Robin	CEO	Sell	125,001	$15.87	$1,983,765.87	10,000
12/3/2015	Jillian B. Thomsen	CAO	Sell	15,000	$15.87	$238,050.00	3,999
11/20/2015	Susan Wang	Director	Sell	85,000	$15.02	$1,276,700.00	20,000
11/11/2015	Gil M. Labrucherie	SVP	Sell	45,000	$13.52	$608,400.00	4,751
11/11/2015	Howard W. Robin	CEO	Sell	125,000	$13.52	$1,690,000.00	10,000
11/11/2015	Jillian B. Thomsen	CAO	Sell	15,000	$13.52	$202,800.00	3,499
10/28/2015	Lutz Lingnau	Director	Sell	12,500	$12.00	$150,000.00	16,450
10/6/2015	Gil M. Labrucherie	SVP	Sell	45,000	$10.99	$494,550.00	4,751
10/6/2015	Howard W. Robin	CEO	Sell	125,000	$10.99	$1,373,750.00	10,000
10/6/2015	Jillian B. Thomsen	CAO	Sell	15,000	$10.99	$164,850.00	3,499
9/23/2015	Gil M. Labrucherie	SVP	Sell	44,999	$13.04	$586,786.96	4,751
9/23/2015	Howard W. Robin	CEO	Sell	124,999	$13.04	$1,629,986.96	10,000
9/23/2015	Jillian B. Thomsen	CAO	Sell	10,000	$13.04	$130,400.00	3,499
8/13/2015	Gil M Labrucherie	SVP	Sell	33,333	$10.89	$362,996.37
8/13/2015	Howard W Robin	CEO	Sell	58,333	$10.89	$635,246.37
7/14/2015	Gil M Labrucherie	SVP	Sell	33,334	$11.78	$392,674.52
7/14/2015	Howard W Robin	CEO	Sell	58,334	$11.78	$687,174.52
6/29/2015	Susan Wang	Director	Sell	30,000	$12.70	$381,000.00
6/19/2015	Robert Chess	Director	Sell	15,000	$11.81	$177,150.00
6/15/2015	Lutz Lingnau	Director	Sell	25,000	$11.15	$278,750.00
12/29/2014	Robert Chess	Director	Sell	29,500	$15.34	$452,530.00
12/22/2014	Jillian B Thomsen	CAO	Sell	5,000	$15.56	$77,800.00
12/1/2014	Gil M Labrucherie	SVP	Sell	120,000	$17.02	$2,042,400.00
12/1/2014	Howard W Robin	CEO	Sell	350,000	$17.01	$5,953,500.00
11/25/2014	Howard W Robin	CEO	Sell	600,000	$15.25	$9,150,000.00
11/24/2014	Gil M Labrucherie	SVP	Sell	10,500	$15.04	$157,920.00
11/24/2014	Howard W Robin	CEO	Sell	132,800	$15.02	$1,994,656.00
11/24/2014	Lutz Lingnau	Director	Sell	15,000	$15.02	$225,300.00
11/3/2014	Gil M Labrucherie	SVP	Sell	9,900	$13.78	$136,422.00
8/5/2013	Roy Whitfield	Director	Sell	12,500	$12.41	$155,125.00	20,000
9/14/2012	Dennis L Winger	Director	Buy	5,000	$9.18	$45,900.00

(Data available from 1/1/2013 forward)

Nektar Therapeutics (NASDAQ NKTR) News Headlines

Source:

Date	Headline
	Nektar Enters Into New Clinical Collaboration With Takeda www.nasdaq.com - April 24 at 10:28 AM
	BRIEF-Nektar And Takeda To Evaluate Combination Of NKTR-214, A CD122-Biased Agonist, And Tak-659, In Liquid And Solid Tumors www.reuters.com - April 24 at 10:28 AM
	Should Vanguard S&P Small-Cap 600 Growth ETF (VIOG) Be on Your Investing Radar? finance.yahoo.com - April 24 at 10:28 AM
	Analysts Expect Nektar Therapeutics (NKTR) Will Post Quarterly Sales of $49.67 Million www.americanbankingnews.com - April 21 at 5:34 AM
	Nektar Therapeutics (NKTR) Now Covered by Seaport Global Securities www.americanbankingnews.com - April 20 at 11:54 AM
	Brokerages Anticipate Nektar Therapeutics (NKTR) Will Announce Earnings of -$0.45 Per Share www.americanbankingnews.com - April 19 at 3:24 AM
	Nektar Therapeutics (NKTR) SVP Jillian B. Thomsen Sells 13,881 Shares www.americanbankingnews.com - April 18 at 7:13 PM
	Nektar Therapeutics (NKTR) Cut to Buy at BidaskClub www.americanbankingnews.com - April 18 at 9:51 AM
	Nektar Therapeutics (NKTR) Given a $125.00 Price Target by HC Wainwright Analysts www.americanbankingnews.com - April 18 at 8:40 AM
	Nektar Therapeutics (NKTR) Announces New Preclinical Data on NKTR-214 and NKTR-262 at 2018 AACR Meetings www.streetinsider.com - April 17 at 10:43 AM
	Today’s Research Reports on Stocks to Watch: Nektar Therapeutics and Merck & Co. finance.yahoo.com - April 17 at 10:43 AM
	Nektar Therapeutics' (NKTR) "Buy" Rating Reiterated at Mizuho www.americanbankingnews.com - April 17 at 8:17 AM
	Nektar Therapeutics (NKTR) Receives Outperform Rating from William Blair www.americanbankingnews.com - April 17 at 12:04 AM
	Today’s Research Reports on Trending Tickers: Valeant Pharmaceuticals and Nektar Therapeutics finance.yahoo.com - April 16 at 10:26 AM
	Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2018 www.prnewswire.com - April 15 at 6:13 PM
	Nektar Therapeutics: What The REVEAL Study Entails seekingalpha.com - April 13 at 10:58 AM
	Nektar Therapeutics (NKTR) Reports Dosing of 1st Patient Phase 1/2 Clinical ... www.streetinsider.com - April 13 at 10:58 AM
	Nektar Therapeutics (NKTR) Earns Buy Rating from Analysts at Piper Jaffray www.americanbankingnews.com - April 13 at 10:13 AM
	Nektar Therapeutics (NKTR) Now Covered by HC Wainwright www.americanbankingnews.com - April 13 at 12:58 AM
	NKTR June 1st Options Begin Trading www.nasdaq.com - April 12 at 11:32 AM
	Nektar Starts Phase I/II Combo for Advanced Solid Tumors finance.yahoo.com - April 12 at 11:32 AM
	Nektar Therapeutics (NKTR) Receives Average Recommendation of "Buy" from Analysts www.americanbankingnews.com - April 12 at 9:13 AM
	Nektar commences Phase 1/2 study of NKTR/262/NKTR-214 combo in solid tumors seekingalpha.com - April 11 at 3:38 PM
	Why CASI Pharmaceuticals Stock Rose Last Week finance.yahoo.com - April 11 at 3:38 PM
	Nektar Therapeutics Begins Dosing Patients In Phase 1/2 REVEAL Clinical Study www.nasdaq.com - April 11 at 11:15 AM
	Roth Capital Analysts Give Nektar Therapeutics (NKTR) a $33.00 Price Target www.americanbankingnews.com - April 11 at 12:43 AM
	NKTR Crosses Above Average Analyst Target www.nasdaq.com - April 10 at 10:54 AM
	Today’s Research Reports on Trending Tickers: Clovis Oncology and Nektar Therapeutics finance.yahoo.com - April 10 at 10:54 AM
	Insider Selling: Nektar Therapeutics (NKTR) SVP Sells 160,000 Shares of Stock www.americanbankingnews.com - April 9 at 10:26 PM
	Nektar Therapeutics (NKTR) SVP Sells $2,035,000.00 in Stock www.americanbankingnews.com - April 9 at 10:26 PM
	Nektar Therapeutics (NKTR) Director Sells $2,303,500.00 in Stock www.americanbankingnews.com - April 9 at 10:26 PM
	Nektar Therapeutics (NKTR) Rating Lowered to Sell at BidaskClub www.americanbankingnews.com - April 9 at 10:19 PM
	Nektar Therapeutics: Top Gainer from S&P 500 in 1Q18 finance.yahoo.com - April 9 at 3:37 PM
	HC Wainwright Reiterates "$125.00" Price Target for Nektar Therapeutics (NKTR) www.americanbankingnews.com - April 9 at 8:25 AM
	Here's Why Nektar Therapeutics Jumped 23% Higher in March www.msn.com - April 8 at 3:38 PM
	Here's Why Nektar Therapeutics Jumped 23% Higher in March finance.yahoo.com - April 8 at 3:38 PM
	Nektar Therapeutics (NKTR) PT Raised to $103 at Mizuho; Epacadostat Failure a Positive www.streetinsider.com - April 7 at 2:17 PM
	These S&P Stocks Jumped 50% in the 1st Quarter finance.yahoo.com - April 7 at 2:17 PM
	Friday Sector Laggards: Healthcare, Industrial www.nasdaq.com - April 6 at 3:40 PM
	Mizuho Raises Nektar Therapeutics (NKTR) Price Target to $103.00 www.americanbankingnews.com - April 6 at 1:23 PM
	BioSci Rounds Report: Unlocking Hidden Values In Omeros, Unum, And Nektar seekingalpha.com - April 5 at 3:37 PM
	Zacks: Brokerages Expect Nektar Therapeutics (NKTR) Will Post Quarterly Sales of $52.42 Million www.americanbankingnews.com - April 4 at 4:54 AM
	Nektar Therapeutics Announces Effective Date of Global Development & Commercialization Collaboration with Bristol-Myers Squibb www.prnewswire.com - April 3 at 5:58 PM
	Analysts’ Recommendations for United Therapeutics in March 2018 finance.yahoo.com - April 3 at 10:55 AM
	Nektar Therapeutics' (NKTR) Buy Rating Reaffirmed at HC Wainwright www.americanbankingnews.com - April 2 at 9:04 AM
	Zacks: Brokerages Anticipate Nektar Therapeutics (NKTR) to Announce -$0.43 Earnings Per Share www.americanbankingnews.com - April 2 at 3:20 AM
	The S&P 500's Biggest Gainers And Losers In A Turbulent First Quarter www.benzinga.com - April 1 at 3:40 PM
	Nektar Therapeutics (NKTR) Rating Reiterated by Jefferies Group www.americanbankingnews.com - April 1 at 11:22 AM
	Nektar Therapeutics (NKTR) Now Covered by Canaccord Genuity www.americanbankingnews.com - March 31 at 8:16 PM
	The S&P 500′s 10 Biggest Winners of the Quarter: Nektar Soars finance.yahoo.com - March 30 at 10:47 AM

Nektar Therapeutics (NASDAQ:NKTR) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Nektar Therapeutics (NASDAQ:NKTR) Income Statement, Balance Sheet and Cash Flow Statement

Nektar Therapeutics (NASDAQ NKTR) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff